膀胱がん治療薬の世界市場

◆英語タイトル:Bladder Cancer: Dynamic Market Forecast to 2026
◆商品コード:GDHC004FS
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年3月29日
◆ページ数:54
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD8,495 ⇒換算¥959,935見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD16,990 ⇒換算¥1,919,870見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD25,485 ⇒換算¥2,879,805見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Bladder Cancer: Dynamic Market Forecast to 2026
Summary

Bladder cancer is a rapidly evolving field in which new developments are constantly influencing the market landscape. The Dynamic Market Forecast is designed to help clients stay abreast of the latest news in the bladder cancer space, including regulatory, commercial, and clinical events as well as understand how all of these events will impact the projected market forecast.

Scope

The Dynamic Market Forecast consists of a slide deck detailing key market-impacting events that have occurred since the last publication of the Bladder Cancer report, which reflects the projected influence of these events on the future bladder cancer market.

The Key Events covered in this Bladder Cancer Dynamic Market Forecast include –
- Developers Turn Focus to Combination Regimens
- New Players Set to Shake Up NMIBC Space

Components of the slide deck include –
- Timeline of market-impacting events
- Key clinical trial landscape updates
- Detailed analysis of the most impactful events, including new primary research to gain Key Opinion Leader perspective
- Overview of updates to the forecast model based on anticipated future impact of events
- Forward-looking events calendar listing expected key updates to the Bladder Cancer competitive space through December 2018

Other events included in the analysis include –
- Regulatory filings
- Approval decisions
- Pricing changes
- Patent litigation
- Clinical trial data announcements
- Clinical trial failures
- Clinical trial timeline updates.

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global bladder cancer market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global bladder cancer market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

【レポートの目次】

Table of Contents
1. Dynamic Market Forecast Overview 4
1.1 Related Reports 5
1.2 Upcoming Related Reports 6
2. Executive Summary 7
2.1 Key Updates To The Bladder Cancer Market Dynamic 8
2.2 Key Events Affecting The Bladder Cancer Competitive Landscape 9-11
2.3 Clinical Trial Landscape Updates 12-13
2.4 Competitive Landscape Changes 14
2.5 Market Insight On Key Events 15
3. Event 1: Developers Turn Focus To Combination Regimens 16
3.1 Key Updates To The Locally Advanced/Metastatic Setting 17-18
3.2 Roche, Tecentriq (atezolizumab) 19-20
3.3 Merck & Co., Keytruda (pembrolizumab) 21-22
3.4 AstraZeneca, Imfinzi (durvalumab) + tremelimumab 23
3.5 Pfizer and Merck KGaA , Bavencio (avelumab) 24
3.6 What Do Physicians Think? 25-30
3.7 Eli Lilly, Cyramza (ramucirumab) 31
3.8 Immunomedics, IMMU-132 32
3.9 Reimbursement In The UK Highlights Cost Effectiveness Concerns 33
3.10 Other Developments Of Interest 34-35
3.11 Summary/Trends 36
3.12 Sources 37-38
4. Event 2: New Players Set To Shake Up NMIBC Space 39
4.1 Key Updates To The NMIBC Space 40
4.2 Insight On Key Events 41
4.3 Summary/Trends 42
4.4 Sources 43
5. Events Calendar 44-45
6. Appendix 46
6.1 Methodology 47
6.2 Primary Research 48-49
6.3 About The Authors 50-51
6.4 About GlobalData 52
6.5 Contact Us 53
6.6 Disclaimer 54





【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[膀胱がん治療薬の世界市場]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆